Study of TLX101-Tx Plus Standard of Care (SoC) Versus SoC Alone for the Treatment of Patients With Recurrent Glioblastoma (IPAX BrIGHT)
NCT 07100730 Brief Summary This global clinical trial which evaluates the efficacy…
Read more arrow_forwardNCT 07100730 Brief Summary This global clinical trial which evaluates the efficacy…
Read more arrow_forwardNCT 04585750 Brief Summary The Phase 2 monotherapy portion of this study…
Read more arrow_forwardNCT 06003621 Brief Summary This phase II study will explore the effect…
Read more arrow_forwardNCT 05356741 Brief Summary This first-in-human (FIH) Phase 1 open-label multicenter dose-escalation…
Read more arrow_forwardNCT 04589845 Brief Summary TAPISTRY is a Phase II, global, multicenter, open-label,…
Read more arrow_forwardInside Rare is a monthly newsletter that shares the latest news, events and stories connecting the rare community.